Euroapi SAS - Asset Resilience Ratio
Euroapi SAS (EAPI) has an Asset Resilience Ratio of 9.16% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check EAPI strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Euroapi SAS's Asset Resilience Ratio has changed over time. See Euroapi SAS (EAPI) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Euroapi SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Euroapi SAS worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €113.80 Million | 8.72% |
| Short-term Investments | €5.70 Million | 0.44% |
| Total Liquid Assets | €119.50 Million | 9.16% |
Asset Resilience Insights
- Limited Liquidity: Euroapi SAS maintains only 9.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Euroapi SAS Industry Peers by Asset Resilience Ratio
Compare Euroapi SAS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Hainan Haiyao Co Ltd
SHE:000566 |
Drug Manufacturers - Specialty & Generic | 3.27% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
Annual Asset Resilience Ratio for Euroapi SAS (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Euroapi SAS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.16% | €119.50 Million ≈ $139.71 Million |
€1.30 Billion ≈ $1.53 Billion |
+3.84pp |
| 2024-12-31 | 5.32% | €79.20 Million ≈ $92.59 Million |
€1.49 Billion ≈ $1.74 Billion |
+2.66pp |
| 2023-12-31 | 2.66% | €42.90 Million ≈ $50.15 Million |
€1.61 Billion ≈ $1.89 Billion |
-1.91pp |
| 2022-12-31 | 4.57% | €79.30 Million ≈ $92.71 Million |
€1.74 Billion ≈ $2.03 Billion |
+2.76pp |
| 2021-12-31 | 1.81% | €29.30 Million ≈ $34.25 Million |
€1.62 Billion ≈ $1.89 Billion |
-7.80pp |
| 2020-12-31 | 9.61% | €153.90 Million ≈ $179.93 Million |
€1.60 Billion ≈ $1.87 Billion |
+1.18pp |
| 2019-12-31 | 8.44% | €133.00 Million ≈ $155.49 Million |
€1.58 Billion ≈ $1.84 Billion |
-- |
About Euroapi SAS
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry;… Read more